Quantcast
Home > Quotes > IMMY
x
IMMY

Imprimis Pharmaceuticals, Inc. Common Stock (IMMY) Quote & Summary Data

$3.35
*  
0.13
3.74%
Get IMMY Alerts
*Delayed - data as of Oct. 17, 2018  -  Find a broker to begin trading IMMY now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 3.53 / $ 3.30
Share Volume
367,242
50 Day Avg. Daily Volume
235,966
Previous Close
$ 3.48
52 Week High / Low
$ 3.61 / $ 1.35
Market Cap
70,515,651
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.78

Intraday Chart

Shares Traded

Share Volume:
367,242
50 Day Avg. Daily Volume:
235,966

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.46

Trading Range

The current last sale of $3.35 is 148.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.53 $ 3.61
 Low: $ 3.30 $ 1.35

Company Description (as filed with the SEC)

We are an ophthalmology-focused pharmaceutical company specialized in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace. We are committed to our company's mission, of delivering high-quality novel medications to physicians and patients at affordable prices. We currently operate our business through several subsidiaries: ImprimisRx, a leading ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient-specific orders; and Surface Pharmaceuticals, Inc. (or Surface), an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary. We also own a passive interest, with royalty stakes on certain drug candidates, in Eton Pharmaceuticals, Inc. (or Eton), a specialty pharmaceutical business utilizing the 505(b)(2) pathway, which Imprimis spun-out in 2017.  ... More ...  

Nasdaq Official Price

Open Price:
$ 3.40
Open Date:
Oct. 17, 2018
Close Price:
$ 3.35
Close Date:
Oct. 17, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info